Key statistics
On Thursday, Avalo Therapeutics Inc (AVTX:NAQ) closed at 9.65, 144.30% above the 52 week low of 3.95 set on Jan 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.69 |
---|---|
High | 10.88 |
Low | 9.60 |
Bid | 9.24 |
Offer | 15.44 |
Previous close | 10.90 |
Average volume | 88.80k |
---|---|
Shares outstanding | 10.39m |
Free float | 9.79m |
P/E (TTM) | -- |
Market cap | 100.30m USD |
EPS (TTM) | -10.96 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
- Avalo Therapeutics to Present at Upcoming Investor Conferences
- Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
- Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
- Avalo Announces Participation in September Investor Conferences
- Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
- Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
- Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
More ▼